3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
147
Breast Neoplasms
108
Lung Neoplasms
93
Carcinoma, Non-Small-Cell Lung
78
Neoplasm Metastasis
68
Glioblastoma
68
Brain Neoplasms
65
Glioma
59
Pancreatic Neoplasms
46
Carcinoma, Renal Cell
43
Multiple Myeloma
41
Squamous Cell Carcinoma of Head and Neck
39
Colorectal Neoplasms
39
Lymphoma, Large B-Cell, Diffuse
37
Neoplasms
34
Melanoma
33
Lymphoma
32
Carcinoma, Hepatocellular
32
Urinary Bladder Neoplasms
31
Ovarian Neoplasms
29
Astrocytoma
28
Sarcoma
25
Oropharyngeal Neoplasms
24
Lymphoma, Follicular
23
Central Nervous System Neoplasms
23
Rectal Neoplasms
22
Uterine Cervical Neoplasms
21
Triple Negative Breast Neoplasms
21
Mouth Neoplasms
21
Lymphoma, Non-Hodgkin
21
Interventions
Carboplatin
12
Pemetrexed
8
pembrolizumab
4
Paclitaxel
4
Cisplatin
4
durvalumab
3
Radiosurgery
3
Gemcitabine
3
selpercatinib
2
pralsetinib
2
osimertinib
2
camrelizumab
2
atezolizumab
2
Docetaxel
2
repotrectinib
1
motexafin gadolinium
1
exemestane
1
entinostat
1
ceralasertib
1
cemiplimab
1
belinostat
1
belagenpumatucel L
1
alectinib
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
TNFSF10 protein, human
1
Radiotherapy
1
Platinum Compounds
1
Oncolytic Virotherapy
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Carcinoma, Bronchogenic
×
Magnetic Resonance Spectroscopy
×
Clear all
NCT00652769
2017-11-01
BOOST
University College London Hospitals
Phase 3
Completed
168 enrolled